RT Journal Article
T1 Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study).
A1 Otero, Remedios
A1 Solier-Lopez, Aurora
A1 Sanchez-Lopez, Veronica
A1 Oto, Julia
A1 Arellano, Elena
A1 Marín, Samira
A1 Jara-Palomares, Luis
A1 Elias, Teresa
A1 Asencio, Maria Isabel
A1 Blasco-Esquivias, Isabel
A1 Rodriguez-de-la-Borbolla, Maria
A1 Sanchez-Diaz, Jose Maria
A1 Real-Dominguez, Macarena
A1 Garcia-Cabrera, Emilio
A1 Rodriguez-Martorell, Francisco Javier
A1 Medina, Pilar
K1 biomarkers
K1 cancer
K1 cancer-associated thrombosis
K1 recurrence
K1 venous thromboembolism
AB The most appropriate duration of anticoagulant treatment for cancer-associated venous thromboembolism (CAT) remains unclear. We have conducted a prospective multicenter study in CAT patients with more than 6 months of anticoagulant treatment to predict the risk of venous thromboembolism (VTE) recurrence after anticoagulation discontinuation. Blood samples were obtained when patients stopped the anticoagulation, at 21 days and at 90 days. In each sample we assessed different coagulation-related biomarkers: D-dimer (DD), high-sensitivity C-reactive protein (hs-CRP), P-selectin (PS), phospholipids, soluble tissue factor, factor VIII and the thrombin generation test. It was evaluated 325 CAT patients and 166 patients were included in the study, mean age 64 ± 17 years. VTE recurrence until 6 months after stopping anticoagulation treatment was 9.87% [95% confidence interval (CI): 6−15]. The biomarkers sub-distribution hazard ratios were 6.32 for ratio DD basal/DD 21 days > 2 (95% CI: 1.82−21.90), 6.36 for hs-CRP > 4.5 (95% CI: 1.73−23.40) and 5.58 for PS > 40 (95% CI: 1.46−21.30) after 21 days of stopping anticoagulation. This is the first study that has identified the DD ratio, hs-CRP and PS as potential biomarkers of VTE recurrence in cancer patients after the discontinuation of anticoagulation treatment. A risk-adapted strategy may allow the identification of the optimal time to withdraw the anticoagulation in each CAT patient.
PB MDPI AG
SN 2072-6694
YR 2022
FD 2022-06-02
LK http://hdl.handle.net/10668/20900
UL http://hdl.handle.net/10668/20900
LA en
NO Otero R, Solier-López A, Sánchez-López V, Oto J, Arellano E, Marín S, et al. Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study). Cancers (Basel). 2022 Jun 2;14(11):2771.
DS RISalud
RD Apr 10, 2025